AlphaFold predicted structure
MYLK2 · Q9H1R3

Mean pLDDT
67.3/ 100
Low
596 residues
Confidence breakdown
- Very high(≥ 90)40%
- Confident(70–90)13%
- Low(50–70)4%
- Very low(< 50)43%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
myosin light chain kinase 2
Annotations refreshed 9 hours ago.
Moderate Evidence (Amber)
Hypertrophic cardiomyopathy
MONOALLELIC, autosomal or pseudoautosomal, NOT imprintedThoracic aortic aneurysm or dissection
Thoracic aortic aneurysm or dissection (GMS)
Sudden death in young people
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownfamilial hypertrophic cardiomyopathy
hypertrophic cardiomyopathy 1
cardiomyopathy
Rare familial disorder with hypertrophic cardiomyopathy
hypertrophic cardiomyopathy
ventricular tachycardia
Left ventricular noncompaction cardiomyopathy
dilated cardiomyopathy 1KK
Parkinson disease
Angiokeratoma corporis diffusum
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Myosin light chain kinase 2, skeletal/cardiac muscle
Ca(2+)/calmodulin-dependent kinase that phosphorylates the regulatory light chain (RLC) of sarcomeric myosin in skeletal and cardiac muscle. Phosphorylation of RLC promotes displacement of myosin cross-bridges from the thick filament backbone toward actin-containing thin filaments, increasing the probability of cross-bridge entry into force-generating states and thereby potentiating contractile force at submaximal Ca(2+) concentrations
MYLK2 · Q9H1R3

Mean pLDDT
67.3/ 100
Low
596 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0